^
Association details:
| Biomarker: | BRAF V600K |
|---|---|
| Cancer: | Cutaneous Melanoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
03/31/2020
Excerpt:
Recommendation 2.3….For patients with resected stage IIIA/B/C/D BRAF-mutant (V600E/K*) disease, the following therapy options should be offered (in no particular order)…pembrolizumab…52 weeks...
DOI:
10.1200/JCO.20.00198
